Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Given every human being is totally unique, it’s no surprise our bodies often behave in different ways. So, while you should ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

led by FreeStyle Libre. The nutritional segment is benefiting from market share gains for its baby formula products. Abbott expects its total 2024 revenue to rise 9.5% to 10% on an organic basis.

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

Roth MKM analyst Scott Fortune initiated coverage on Turning Point Brands, Inc. TPB with a Buy rating and announced a price ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Gov. Greg Abbott and the Texas Film Commission along with the Bob Bullock State History Museum announced the revival of the Texas Focus Film Series, according to a news release from Abbott’s ...

Abbott Labs' key product line in its diabetes care segment is the FreeStyle Libre, a portfolio of continuous glucose monitoring (CGM) devices that allow diabetes patients to keep track of their ...

Designed to track glucose in real time, Lingo is based on Abbott's FreeStyle Libre CGM technology ... It is also accessible in the UK. Per a Grand View Research report, the global CGM devices ...